Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09AGG
|
|||
| Former ID |
DNCL003575
|
|||
| Drug Name |
GSK2890457
|
|||
| Synonyms |
GSK-2890457
Click to Show/Hide
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endogenous gut peptide (EGP) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01725126) To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes. U.S. National Institutes of Health. | |||
| REF 2 | Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014 Aug;23(8):1055-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.